Investor Presentaiton

Q3FY24 - Quarterly Performance Revenue Breakup (INR Mn) Revenue Breakup (%) - Q3FY24 6% 4% 2% Revenue Division Q3FY24 Q3FY23 Q2FY24 12% A) API Revenue 463 426 778 B) Formulation 76% B1) Formulation - Exports (incl profit share, license income, export service income & Subsidiaries) ■ Export Formulation 6,056 3,337 7,923 ■Crop Health Science ■Domestic Formulation ■ API ■ Other operating and non-operating income B2) Formulation - Domestic 994 1,011 1,025 Formulations Total Revenue (B1 + B2) 7,050 4,348 8,948 Revenue Breakup (%) - 9MFY24 4% 6% 3% C) Crop Health Sciences 141 99 558 11% D) Other Operating & Non - operating incomes 302 260 324 Consolidated Total Revenue 7,956 5,133 10,608 Natco Pharma Limited - Earnings Presentation - Q3FY24 ■ Export Formulation ■Crop Health Science ■ Other operating and non-operating income 76% ■ Domestic Formulation ■ API

View entire presentation